Três sociedades neurológicas, incluindo a AAN, emitem forte diretriz de posicionamento sobre o aducanumabe.

Three Neurologic Societies, Including the AAN, Issue Strong Position Statement on Aducanumab – Neurology Today

Ver diretriz: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement – Neurology

Conteúdos relacionados:

Editorial: Aducanumab for Alzheimer’s disease?

FDA approvement of Alzheimer’s drug sparks controversy among doctors.

Comentário no Twitter

Decisions With Patients and Families Regarding #Aducanumab in Alzheimer Disease, With Recommendations for Consent—Read the full AAN @AANMember Position Statement: https://t.co/ckoIVRi4DE #Neurology pic.twitter.com/q8TSU67zm9

— Neurology Journal (@GreenJournal) November 19, 2021